A registered study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase not reported
- Study design
- RANDOMIZED · PARALLEL · PREVENTION · QUADRUPLE
- Evidence population
- Human clinical study registration
- Participants
- 108
- Population
- ALL · 65 Years
- Duration
- 2023-10-25 to 2024-12-31
- Intervention
- Dexmedetomidine Injection [Precedex]; Lidocaine IV; normal saline
- Comparator
- Control group
- Outcomes measured
- Postoperative change of cerebrospinal-plasma albumin ratio (CPAR) — From the baseline to immediate postoperative values; The changes of inflammatory biomarker level in blood — From the baseline to immediate postoperative state and postopera…; The changes of neuronal damage biomarker level in blood — From the baseline to immediate postoperative state and postop…; The changes of inflammatory, neuronal damage, BBB permeability biomarker level in blood — From the baseline to immediat…; The incidence of postoperative delirium — From postoperative day 0 to 5; The subtype of postoperative delirium — From postoperative day 0 to 5; Delirium Rating Scale Revised (DRS-R-98) — From postoperative day 0 to 5; Onset and duration of delirium — From postoperative day 0 to 5; Pain score (NRS) — From postoperative day 0 to 5; Subjective sleep quality — From postoperative day 0 to 5; Montreal cognitive Assessment (MoCA) — at baseline and 7 days after surgery or at discharge; Ideal outcome of pancreatoduodenectmoy — postoperative day 30; non-delirium complications within 30 days after surgery — Within 30 days after surgery
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Blood-brain barrier ageing · 100%Title contains controlled term: blood-brain barrier. Abstract contains controlled term: blood-brain barrier. Title supplies longevity context: elderly. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.